211 related articles for article (PubMed ID: 17659481)
1. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer.
Chen L; Pankiewicz KW
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):403-12. PubMed ID: 17659481
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment.
Chen L; Wilson D; Jayaram HN; Pankiewicz KW
J Med Chem; 2007 Dec; 50(26):6685-91. PubMed ID: 18038969
[TBL] [Abstract][Full Text] [Related]
3. Inosine 5'-monophosphate dehydrogenase inhibitors for the treatment of autoimmune diseases.
Ratcliffe AJ
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):595-605. PubMed ID: 17002220
[TBL] [Abstract][Full Text] [Related]
4. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Malek K; Boosalis MS; Waraska K; Mitchell BS; Wright DG
Leuk Res; 2004 Nov; 28(11):1125-36. PubMed ID: 15380335
[TBL] [Abstract][Full Text] [Related]
5. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
6. A potent "fat base" nucleotide inhibitor of IMP dehydrogenase.
Wang W; Hedstrom L
Biochemistry; 1998 Aug; 37(34):11949-52. PubMed ID: 9718319
[TBL] [Abstract][Full Text] [Related]
7. Cofactor-type inhibitors of inosine monophosphate dehydrogenase via modular approach: targeting the pyrophosphate binding sub-domain.
Felczak K; Chen L; Wilson D; Williams J; Vince R; Petrelli R; Jayaram HN; Kusumanchi P; Kumar M; Pankiewicz KW
Bioorg Med Chem; 2011 Mar; 19(5):1594-605. PubMed ID: 21324702
[TBL] [Abstract][Full Text] [Related]
8. Tiazofurine ICN Pharmaceuticals.
Grifantini M
Curr Opin Investig Drugs; 2000 Oct; 1(2):257-62. PubMed ID: 11249583
[TBL] [Abstract][Full Text] [Related]
9. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
10. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
[TBL] [Abstract][Full Text] [Related]
11. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
12. Novel inhibitors of inosine monophosphate dehydrogenase in patent literature of the last decade.
Petrelli R; Vita P; Torquati I; Felczak K; Wilson DJ; Franchetti P; Cappellacci L
Recent Pat Anticancer Drug Discov; 2013 May; 8(2):103-25. PubMed ID: 23016672
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of the inosine 5'-monophosphate dehydrogenase (IMPDH) inhibitors.
Cholewiński G; Iwaszkiewicz-Grześ D; Prejs M; Głowacka A; Dzierzbicka K
J Enzyme Inhib Med Chem; 2015; 30(4):550-63. PubMed ID: 25198892
[TBL] [Abstract][Full Text] [Related]
14. NAD-based inhibitors with anticancer potential.
Felczak K; Vince R; Pankiewicz KW
Bioorg Med Chem Lett; 2014 Jan; 24(1):332-6. PubMed ID: 24269162
[TBL] [Abstract][Full Text] [Related]
15. Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor.
Jain J; Almquist SJ; Heiser AD; Shlyakhter D; Leon E; Memmott C; Moody CS; Nimmesgern E; Decker C
J Pharmacol Exp Ther; 2002 Sep; 302(3):1272-7. PubMed ID: 12183689
[TBL] [Abstract][Full Text] [Related]
16. Inosine monophosphate dehydrogenase as a target for antiviral, anticancer, antimicrobial and immunosuppressive therapeutics.
Braun-Sand SB; Peetz M
Future Med Chem; 2010 Jan; 2(1):81-92. PubMed ID: 21426047
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(2,3,5-triazoyl)mycophenolic amide and mycophenolic epoxyketone as novel inhibitors of human IMPDH.
Sunohara K; Mitsuhashi S; Shigetomi K; Ubukata M
Bioorg Med Chem Lett; 2013 Sep; 23(18):5140-4. PubMed ID: 23937979
[TBL] [Abstract][Full Text] [Related]
18. A three-dimensional pharmacophore model for IMPDH inhibitors.
Yang N; Wang J; Li J; Wang QH; Wang Y; Cheng MS
Chem Biol Drug Des; 2011 Jul; 78(1):175-82. PubMed ID: 21507206
[TBL] [Abstract][Full Text] [Related]
19. Phosphonic acid-containing analogues of mycophenolic acid as inhibitors of IMPDH.
Watkins WJ; Chen JM; Cho A; Chong L; Collins N; Fardis M; Huang W; Hung M; Kirschberg T; Lee WA; Liu X; Thomas W; Xu J; Zeynalzadegan A; Zhang J
Bioorg Med Chem Lett; 2006 Jul; 16(13):3479-83. PubMed ID: 16621550
[TBL] [Abstract][Full Text] [Related]
20. Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep.
Dzidic A; Prgomet C; Mohr A; Meyer K; Bauer J; Meyer HH; Pfaffl MW
J Vet Med A Physiol Pathol Clin Med; 2006 May; 53(4):163-9. PubMed ID: 16629948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
